| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b5b66b8be58391fe948a625b407ec8a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e3830f35387a1c32061dea3ee310851 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-716
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-716
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4738 |
| filingDate |
2019-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d10e1243388120ea36cbcac842e0b66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6c79de7523045ddef855d6a8a80c5e8 |
| publicationDate |
2021-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3765018-A1 |
| titleOfInvention |
Beta glucan and cd40 agonist combination immunotherapy |
| abstract |
The present invention relates to the combination of β-glucan and a CD40 agonist for cancer immunotherapy. The combination therapy shows synergistic anti-tumor activity that is dependent on T cells. Surprisingly, the combination therapy is effective against poorly immunogenic tumors. |
| priorityDate |
2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |